NCT07096037

Safety and Efficacy of Urtica Dioica Cataplasm in the Management of Osgood-Schlatter Disease in Young Athletes

Evaluation of Safety and Efficacy of Urtica Dioica Cataplasm in the Management of Osgood-Schlatter Disease in Young Athletes: A Study Protocol for Randomized, Double-blind, Placebo Controlled Clinical Trial

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: Faculty of Medicine, Sousse · Academic / Other
• Sex: Male
• Age: 7 Years – 15 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this clinical trial is to evaluate the efficacy and safety of a topical Urtica dioica cataplasm in managing knee pain and functional limitations in athletic children diagnosed with Osgood-Schlatter Disease. Efficacy will be assessed through changes in knee pain using the Visual Analog Scale (VAS) and functional outcomes using the Knee Injury and Osteoarthritis Outcome Score (KOOS). Three groups will be tested: * UDC Group: topical application of Urtica dioica cataplasm * Standard Care Group: oral vitamin D supplementation and physical rest * Placebo Group: topical application of a placebo cataplasm using Beta vulgaris subsp. cicla

Conditions

• Osgood-Schlatter Disease

Interventions

Type	Name	Description
OTHER	Urtica dioica cataplasm	Participants will receive a warm Urtica dioica cataplasm applied topically on the affected knee, once daily for 60 minutes, three times per week (on alternate days) over a 6-week period.
OTHER	Placebo	Participants will receive a placebo cataplasm, matched in texture, color, and odor to the active treatment. The placebo is inert and safe for pediatric topical use.
DRUG	Vitamin D	Participants will receive oral vitamin D.
BEHAVIORAL	Resting conditions	Reduction in physical activity based on orthopedic advice.

Timeline

• Start date: 2025-09-01
• Primary completion: 2025-09-15
• Completion: 2026-09-30
• First posted: 2025-07-31
• Last updated: 2025-08-01